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ABSTRACT 
 
OBJECTIVE: The objective of this systematic EBM review is to determine whether or not the 
administration of depot medroxyprogesterone acetate injections every three months are effective 
in decreasing pain associated with endometriosis in premenopausal women. 
 
STUDY DESIGN: A review of two randomized controlled trials and one randomized 
comparative trial comparing pain improvement from depot medroxyprogesterone acetate 
(DMPA) injections at different time intervals and/or in comparison to other hormonal birth 
control methods in premenopausal patients suffering from endometriosis.  
 
DATA SOURCES:  Randomized controlled trials and a randomized comparative trial were 
found using PubMed and Ovid MEDLINE databases.  
 
OUTCOME MEASURED: Outcomes were measured for reduction of pain by a verbal rating 
scale and/or a 10-cm or a 100-mm visual analog scale.  
 
RESULTS: Wong et al found that the pain score was significantly reduced all through the study 
period as long as the therapy of 150mg DMPA intramuscular injection every three months was 
continued (in all patients but one). Both Cheewadhanaraks et al and Walch et al showed a 
decreased in pain scores with DMPA in comparison to the control, but neither article calculated 
statistics comparing these scores to the baseline, therefore results are inconclusive whether or not 
pain associated with endometriosis is decreased with administration of DMPA injections every 
three months in premenopausal women.  
 
CONCLUSION: Based on the articles reviewed, one of the articles showed evidence that 150mg 
injections of DMPA administered every three months is an effective means of decreasing 
endometriosis-associated pain in premenopausal women. The other two articles had inconclusive 
results, therefore further research is warranted. 
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INTRODUCTION 
 Endometriosis is a chronic and recurrent condition where endometrial tissues grow in 
areas of the body outside the uterus leading to pelvic pain, dysmenorrhea, and infertility.1 
Normally each month the cells lining the uterus increase in thickness following the release of 
hormones from the ovaries. These cells then shed from the endometrial lining during a woman’s 
menstrual period. If instead the endometrial cells implant outside the uterus, endometriosis 
occurs resulting in tissue implanting in various organs in the pelvic region. This misplaced tissue 
is not shed monthly but it stays in place and grows during menstruation thereby frequently 
causing cyclic bleeding, scarring, and dysmenorrhea.2  
 It is estimated approximately 6-20% of reproductive-age women1 are affected by 
endometriosis thereby afflicting approximately 167 million women worldwide and 8.5 million in 
North America4. The prevalence of endometriosis is assumed to be around 10% of women of 
reproductive age3, 5 making it a prominent concern for healthcare providers.  The average cost of 
endometriosis is $12,500/year per woman ($8,200 lost in work productivity; $4,000 for direct 
health care costs). Costs were higher with increasing severity of disease and the presence of 
dysmenorrhea6, although they may vary according to socioeconomic status and individual 
insurance policies regarding coverage of treatment options. In the United States alone, 
endometriosis-associated costs are estimated to be $22 billion annually.4 Yearly healthcare visits 
vary, however a woman with endometriosis sees 4-5 doctors prior to being correctly diagnosed.6  
 This estrogen-dependent condition is most commonly associated with dysmenorrhea but 
it may also cause dyspareunia, infertility, fatigue, dysuria, pain during bowel movements, and 
other gastrointestinal symptoms.1, 6 Endometriosis is usually diagnosed between 25-35 years of 
age although the condition is thought to have developed around the beginning of a girl’s 
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menstrual cycle. Women with a family history of the condition, who never had children, 
developed their period at a young age, have frequent or long periods, or have a closed hymen are 
more likely to develop endometriosis.2 The cause of endometriosis is unknown; however, the 
retrograde menstruation theory proposes that during a woman’s cycle part of the menstrual tissue 
backs up through the oviducts then implants and grows in the abdomen. There are theories that 
this tissue is sent from the uterus to other body parts via the lymph or blood system.6 
Additionally, it has been proposed that stem cells, genetics, dysfunctional immune responses, 
and environmental sources all may contribute in some way to this multi-factorial condition.4  
 Pain medication, hormonal therapy, surgery, traditional Chinese medicine, nutritional 
changes, homeopathy, allergy control, and immune therapy are all treatment options for 
endometriosis, as there is no cure.6 Treatment depends on age, severity of symptoms and disease, 
and whether a woman wants to become pregnant in the future.2 Mild symptoms may be managed 
with exercise, relaxation techniques, and non-steroidal anti-inflammatory drugs (NSAIDs). In 
order to halt the disease progression, hormone medications have been shown to reduce most 
symptoms.2 The gold standard for women who have no improvement with other treatment 
methods and are still experiencing severe pain is pelvic laparascopic excision surgery to remove 
all endometrial implants and adhesions.2, 4 Hysterectomy, including ovary removal of ovaries, is 
a last resort for persistent symptoms in women who do not wish to have future children.2  
 For many women with moderate and severe endometriosis, they still run a high risk of 
symptoms associated with the disease after conservative surgery. Studies have shown that 
hormonal therapies are equally effective in the control of endometriosis-associated pain, but their 
side effects and costs differ.7 Because hormonal therapy is less invasive and more affordable 
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than surgery and often offers less systemic side effects than antiestrogrens1, many hormonal 
methods have been utilized to determine their effect on endometriosis-associated dysmenorrhea.  
 Depot medroxyprogesterone acetate (DMPA), a birth control drug, is a 17-hydroxy 
derivate progestogen with moderate androgenic activity that is administered intramuscularly in 
attempt to decrease endometriosis-associated pain. This paper evaluates three randomized 
controlled/comparative trials comparing the effectiveness of DMPA injections every three 
months in decreasing endometriosis-associated pain in premenopausal women. This systemic 
review compares DMPA  injections given every three months to DMPA administered every 
month for six months followed by every three months, a levonorgestrel-releasing intrauterine 
system, and a single-rod etonogestrel-containing contraceptive implant.1, 3, 7 All regimens are 
primarily hormonal birth control methods.  
OBJECTIVE 
 The objective of this systematic review is to determine whether or not the administration 
of depot medroxyprogesterone acetate injections every three months are effective in decreasing 
pain associated with endometriosis in premenopausal women. 
METHODS 
 The population selected for this study included premenopausal women between the ages 
of eighteen and fifty years old who were experiencing endometriosis-associated pain. The 
intervention applied in the systemic review was 150mg DMPA intramuscular injection given 
every three months. The comparisons were to 150mg DMPA intramuscular injection 
administered every month for six months followed by every three months, a levonorgestrel-
releasing intrauterine system (Mirena), a single-rod etonogestrel-containing contraceptive 
implant (Implanon).1, 3, 7 The outcome measured is reduction of pain and was evaluated by a 
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verbal rating scale and a 10-cm or a 100-mm visual analog scale according to specific criteria. 
The types of studies included three randomized controlled/comparative trials. 
 A detailed literature search was conducted using PubMed and Ovid MEDLINE. The 
searches were conducted from December 2011 until December 2012. The keywords searched for 
were “Medroxyprogesterone Acetate”, “Depoprovera”, and “Endometriosis”. Each article was 
published originally in English in peer reviewed journals. The articles were researched and 
selected based on relevance and patient oriented outcomes that matter to them (POEMS). 
Inclusion criteria are composed of studies that were randomized controlled/comparative trials 
that included POEMS and administered a DMPA dosage of 150mg. Exclusion criteria include 
articles with patients under the age of eighteen and over the age of fifty years old and those that 
were published prior to 2009. Statistics reported or used include p-value, baseline median, 95% 
confidence interval (CI), student t-test, Experimental Event Rate (EER), Controlled Event Rate 
(CER), Relative Benefit Increase (RBI), Absolute Benefit Increase (ABI), and Numbers Needed 
to Treat (NNT). Table 1 includes the demographics of the studies analyzed in this review.  
Table 1: Demographics & Characteristics of Included Studies  
Study Type # 
Participants 
Age 
(years) 
Inclusion Criteria Exclusion Criteria W/
D 
Interventions 
Cheewa
dhanara
ks et al  
(2009) 
RCT 112 18-46 
years 
Premenopausal 
women from 18 to 46 
years of age who had 
endometriosis-
associated pain for at 
least 6 months and 
did not wish to 
conceive in the next 2 
years or more 
 
Medical therapies for 
endometriosis other 
than NSAIDs within 
last 6 months;  
contraindications to 
DMPA; request for 
extirpative surgery; 
ovarian endometioma 
>2cm; other pelvic 
pathology; GI, urologic, 
or orthopedic diseases 
42 150 mg 
DMPA 
injections 
every month 
for 6 months 
then every 3 
months for 
15 months or 
every 3 
months for 
15 months 
Walch 
et al 
(2009) 
RCT 41 22-44 
years 
Women with 
symptomatic Stage I-
IV endometriosis 
proven by 
laparoscopy or 
laparotomy prior to 
inclusion; 
dysmenorrhea and 
Desire to conceive; +  
hCG test; suspicious 
Pap; uterine or adnexal 
anomalies 
endometriosis; large 
adenomas; any 
malignancy; performed 
hysterectomy, C/I to 
11 Implanon 
(subdermal 
implantation
) or 150 mg 
DMPA 
injections 
every 3 
months  
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menstrual 
irregularities 
associated with 
endometriosis and no 
desire to conceive 
within the next 12 
months; pre-
menopausal; grade 
severity of 
dysmenorrhea, 
nonmenstrual pelvic 
pain, dyspareunia on 
a 100-mm visual 
analog scale with a 
mean score >50 over 
a period of 14 days, 
including one 
menstrual bleeding 
progestins; use of an 
oral contraceptive pill 
within 1 month; l use of 
injectable hormonal 
treatments during the 
last 3 months before 
study  
Wong et 
al 
(2010) 
RCT 30 ≥ 
30 
years 
Premenopausal 
patients age  ≥30, 
history of surgery 
performed in past 5 
years for moderate or 
severe endometriosis; 
no evidence of lesion 
recurrence or 
osteoporosis from a 
DEXA scan on 
lumbar spine/hip; no 
desire for pregnancy 
within 3 years; 
patient agreed to 
hormonal therapy 
None given 10 Mirena 
(LNG-IUS) 
or 150 mg 
MPA every 
3 months 
 
OUTCOMES MEASURED 
 All outcomes measured were based on relevance to Patient Oriented Evidence that 
Matters, or POEMS. Although all three of the studies had multiple POEMS, this systematic 
review focuses specifically on the outcome of pain associated with endometriosis. One of the 
articles measured pain on a verbal rating scale from 0-3 (0 – no pain, 1 – mild pain not requiring 
intervention, 2 – moderate pain requiring analgesics, 3 – intolerable pain).7 The second article 
measured pain using a 100-mm visual analog scale where a score higher than fifty over a 
fourteen day period was necessary for inclusion.1 The third article utilized both a verbal rating 
scale from 0-3 (0 – no pain, 1 – no absence from work but decrease efficiency, 2 – absence from 
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work <1 day per cycle, 3 – absence from work ≥ 1 day per cycle) and a 10-cm visual analog 
scale from 0-10 (0 – absence of pain, 10 – unbearable pain) to measure pain.3  
RESULTS 
 All three articles presented in this systematic review are randomized 
controlled/comparative trials that compare 150mg of DMPA intramuscular injections every three 
months to other birth control methods or DMPA administered during different time intervals to 
determine its efficacy at decreasing endometriosis-associated pain in premenopausal women.1, 3, 7  
 Wong et al conducted a randomized controlled trial comparing levonorgestrel-releasing 
intrauterine system (LNG-IUS, or Mirena) to DMPA as long-term maintenance therapy for 
patients with moderate and severe endometriosis. The study began with thirty premenopausal 
patients >30 years of age with history of conservative surgery performed within five years for 
moderate to severe endometriosis, no evidence of lesion recurrence or osteoporosis from a 
DEXA scan on the lumbar spine or hip, no desire for pregnancy within three years, and the 
patient agreed to receive hormonal therapy. There were no exclusion criteria. Fifteen of the 
women were randomized into the LNG-IUS group and fifteen into the DMPA group.7  
 The women in the LNG-IUS group had the product inserted into the uterus where it 
released levonorgesterol at a rate of 20 ug/24 hrs for up to five years at a virtually constant rate. 
The 150mg DMPA intramuscular injections were administered every three months for three 
years. Follow up in the first year was every three months, followed by every six months in the 
second and third years. Zero patients were lost to follow-up although ten patients discontinued 
the interaction due to adverse side effects – two from the LNG-IUS group and eight from the 
DMPA group. As a result, the LNG-IUS had a better compliance rate.7  
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 After initiation of treatment, there was a decrease in the pain scores three months later 
with both LNG-IUS (p<0.02) and DMPA (p<0.002), as well as a decrease throughout the rest of 
the study for all patients except one on DMPA. As shown in Table 2, there was a change in the 
mean from the baseline for LNG-IUS of 1.5 and DMPA of 1.2. At thirty-six months, LNG-IUS 
was found to be significantly lower in pain scores versus DMPA although no statistics were 
reported. Overall, the pain score throughout the study between the two variables was statistically 
significant with a p-value of <0.025. Both the control and intervention were found to be effective 
in decreasing pain associated with endometriosis when compared to the baseline pain level.7  
Table 2: Summary of Pain Scores Over 36 Months  
 # of 
Patients  
Pain Score 
Change in Mean 
From Baseline  
Pain Score p-value 
from Baseline-3mo 
p-value at 36mo 
between LNG-IUS 
and Depot MPA 
LNG-IUS 15 1.5 (1.6-0.1) <0.02 <0.025 
Depot MPA 15 1.2 (1.9-0.7) <0.002 <0.025 
*Statistical comparison was by Student t test  
 
 Walch et al conducted a randomized controlled trial comparing the therapeutic efficacies 
of Implanon, a single-rod etonogestrel-containing contraceptive implant administered 
intradermally to prevent ovulation for at least three years, and 150mg DMPA intramuscular 
injections every three months in relieving pain associated with endometriosis in premenopausal 
women. The study began with forty-one premenopausal patients between 22-44 years of age with 
symptomatic endometriosis who had no desire to conceive in the next twelve months and had a 
mean VAS score >50 over fourteen days including one menstrual bleeding. Patients were 
excluded with a desire to conceive, a positive hCG test, a suspicious Pap smear, uterine or 
adnexal anomalies, large adenomas, any malignancy, performed hysterectomy, contraindications 
to progestins, oral contraceptive pill usage within one month, or injectable hormonal treatments 
during the last three months before study entry. Eleven women withdrew due to adverse side 
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effects, the desire to conceive, or a dwelling change – four from the Implanon group and seven 
from the DMPA group, but this dropout rate was not considered statistically significant.1  
 During the one year study, there was a marked reduction in pain intensity after 
administration of both Implanon and DMPA. This study focused its primary outcome measure in 
regards to pain reduction at the six month mark when compare to baseline.1 Since the 
dichotomous data was given, the control event rate (CER), experimental event rate (EER), 
absolute benefit increase (ABI), relative benefit increase (RBI), and number needed to treat 
(NNT) were calculated. The CER is the percentage of patients receiving Implanon whereas the 
EER is those receiving DMPA. The ABI is the increase of a good event as a result of DMPA. 
The RBI is the proportional increase in the rate of good outcomes between the Implanon and 
DMPA groups. The number needed to treat determines the number of people needed to be 
treated in order to prevent one patient from experiencing pain associated with endometriosis. 
 The mean decrease in VAS scores (quantifying pain intensity) after the first six months 
was 68% with a 95% CI (53-83) for the Implanon group and 53% with a 95% CI (28-79) in the 
DMPA group. The NNT value was -6 signifying that for every six patients treated with 
Implanon, one less patient experienced pain associated with endometriosis compared to DMPA, 
as shown in Table 3. The difference between these two groups was not shown to be statistically 
significant with p=0.36, where significance was achieved when p<0.05. On month six, the VAS 
score for the Implanon group was not statistically significant compared to the DMPA group with 
p=0.69. There was no statistical difference in VAS scores between treatment groups when 
analyzed (p=0.8). When comparing Implanon to DMPA, the difference in VAS scores was not 
statistically significant. When compared to baseline, each regimen individually showed a marked 
decrease in pain scores although analysis was not performed making the data inconclusive.1  
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Table 3: Analysis of Pain Reduction at 6 Months in Relevance to RBI/ABI/NNT 
 Controlled 
Event 
Rate 
(CER) 
Experimental 
Event Rate 
(EER) 
p-value  Relative 
Benefit 
Increase 
(RBI) 
Absolute 
Benefit 
Increase 
(ABI) 
Numbers 
Needed to 
Treat 
(NNT) 
Walch et al 0.68 0.53 p=0.36 0.221 -0.15 -6 
 
 Cheewadhanaraks et al conducted a randomized comparative trial comparing 150 mg 
DMPA intramuscular injections every month for six months then every three months for fifteen 
months (regimen A) to injections every three months for fifteen months (regimen B) to 
determine the optimal interval in the long-term treatment in pain associated with endometriosis. 
Patients were seen for a follow-up visit every three months. The study was conducted with 112 
premenopausal women 18-46 years of age who had endometriosis-associated pain for at least six 
months and did not wish to conceive in the next two years or more. Exclusion criteria included 
medications for endometriosis besides NSAIDs within last six months, contraindications to 
DMPA, extirpative surgery request, ovarian endometioma >2cm (ruled out with transvaginal 
ultrasound), other pelvic pathology, or known GI, urologic, and orthopedic diseases. In the two 
months prior to the study, an initial laparoscopic diagnosis of endometriosis was performed and 
staged according to the American Fertility Society classification system. Forty-two women 
withdrew from the study, twenty-one from each regimen, due to persistent pain and adverse side 
effects. This was not statistically significant since p=0.032 (p<0.05 was considered significant).3  
 Throughout the fifteen month study, there was a continual trend resulting in a decrease in 
the pain scores between patients in both treatment regimens. At the six month time interval, there 
was statistical significance achieved where there was a larger decrease in pain in regimen A in 
comparison to regimen B as seen in Table 4. This table also shows the verbal rating scores 
(VRS) during the six month time interval that was analyzed and found to be statistically 
significant being the p-values were <0.05. Regardless of this outcome, there were no statistics 
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conducted comparing pain scores from either regimen to baseline pain before beginning the 
study. Therefore, although statistical significance was achieved at the sixth month time interval 
when comparing regimen A to regimen B, in terms of answering the proposed question of this 
review the results would have to be considered inconclusive due to lack of statistical analysis.3 
Table 4: Verbal Rating Scale for Pain Intensity  
 0  1  2  3 p-value 
Regimen A 35 8 0 0 0.012 
Regimen B 26 12 6 1 0.009 
 
DISCUSSION 
 All three studies showed a decrease in pain scores in comparison to the control in each 
study, although Walch et al is the only study that showed statistical significance in reduction of 
pain scores from DMPA when compared to baseline. DMPA is widely available with a 
prescription from a healthcare practitioner. Most insurances that cover the birth control pill cover 
the MDPA shot as well, although this can vary per individual. For those without insurance, 
Planned Parenthood offers the shot at a discounted rate.8 DMPA is contraindicated in patients 
with pregnancy or as a diagnostic test for pregnancy, thrombophlebitis, thromboembolic 
disorders, cerebral vascular disease, breast malignancy, hypersensitivity to DMPA, liver disease, 
or undiagnosed vaginal bleeding. Warnings and precautions of the drug include loss of bone 
mineral density, thromboembolic disorders, cancer risks, ectopic pregnancy, anaphylaxis, liver 
disturbances, convulsions, depression, bleeding irregularities, weight gain, carbohydrate 
metabolism reduction, fluid retention, delayed fertility, and sexually transmitted diseases.9 
 The black box warning notes that DMPA causes increased osteoporotic effects the longer 
it is administered, may remain after the injections cease, and may be irreversible. Pfizer, the 
DMPA drug manufacturer, and the Food and Drug Administration advise that it should not be 
used over a two year period unless no other options are feasible due to bone loss concerns. It is 
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primarily used as a progestin hormone birth control method to prevent pregnancy. It causes a 
change in menstrual periods of most women where they experience an increase or decrease in 
flow, increased spotting, or amenorrhea.9 DMPA is also being used in nine states as a form of 
chemical castration where it acts as a sexual suppressant in male sex offenders.10 
 All three of the articles reviewed had limitations to the studies which included small 
sample sizes with significant drop out rates and no blinding. If the study sizes were larger, it is 
possible that the results may have been different. In the future, it may be of interest to administer 
DMPA injections to one group and placebo shots to another group, as long as the women 
involved did not have concerns about becoming pregnant. This way both the patients and the 
shot administrators would be unaware of which injection each woman was receiving making it a 
double blinded study. It would also be helpful to perform statistical analysis on the decrease in 
pain levels when compared to the baseline. This would show the effectiveness of each drug 
individually, in addition to the comparison to other methods if warranted in the particular study. 
CONCLUSION 
 According to the three articles selected for this systemic review, Walch et all showed that 
the administration of depot medroxyprogesterone acetate injections every three months is 
effective in decreasing pain associated with endometriosis in premenopausal women.1 Wong et 
al and Cheewadhanaraks et al were found to be inconclusive. Although, all studies showed a 
significant decrease in pain levels when compared to the control, the latter two studies did not 
publish data comparing DMPA pain levels throughout the study to the initial baseline 
measurements. Future study is warranted using a larger double blinded multicultural study that 
looks at the administration of DMPA to a placebo and calculates statistical analysis on pain 
reduction for the drug throughout the study in comparison to baseline.  
  
REFERENCES 
 
1. Walch, K., Unfried, G., Huber, J., Kurz, C., van Trotsenburg, M., Pernicka, E., et al. (2009). 
Implanon versus medroxyprogesterone acetate: Effects on pain scores in patients with 
symptomatic endometriosis--a pilot study. Contraception, 79(1), 29-34.  
 
2. Endometriosis. PubMed Health. U.S. National Library of Medicine – The World’s Largest 
Medical Library. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001913/ Accessed 
November 24, 2012. 
 
3. Cheewadhanaraks, S., Peeyananjarassri, K., Choksuchat, C., Dhanaworavibul, K., Choobun, 
T., & Bunyapipat, S. (2009). Interval of injections of intramuscular depot medroxyprogesterone 
acetate in the long-term treatment of endometriosis-associated pain: A randomized comparative 
trial. Gynecologic and Obstetric Investigation, 68(2), 116-121.  
 
4. Endometriosis. Endometriosis Foundation of America. 
http://www.endofound.org/endometriosis. Accessed November 24, 2012. 
 
5. Cost of endometriosis is driven by pain. World Endometriosis Research Foundation. 
http://endometriosis.org/news/endocost-cost-of-endometriosis-driven-by-pain/. Accessed 
September 16, 2012. 
 
6. What is Endometriosis? The Endometriosis Association. Endo-Online The voice of the 
Endometriosis Association. http://www.endometriosisassn.org/healthcareproviders.html 
Accessed November 24, 2012. 
 
7. Wong, A. Y., Tang, L. C., & Chin, R. K. (2010). Levonorgestrel-releasing intrauterine system 
(mirena) and depot medroxyprogesterone acetate (depoprovera) as long-term maintenance 
therapy for patients with moderate and severe endometriosis: A randomised controlled trial. The 
Australian & New Zealand Journal of Obstetrics & Gynaecology, 50(3), 273-279.  
 
8. Birth Control. Planned Parenthood Website. http://www.plannedparenthood.org/health-
topics/birth-control-4211.htm. Accessed November 24, 2012.  
 
9. Depo-Provera. Drugs.com. http://www.drugs.com/pro/depo-provera.html. Accessed 
November 24, 2012.  
 
10. Spalding, L. H. (1998). Florida's 1997 Chemical Castration Law: A Return to the Dark Ages. 
1998 Florida State University Law Review. 
http://www.law.fsu.edu/journals/lawreview/frames/252/spalfram.html. Accessed November 24, 
2012.  
 
 
 
 
